Endocrinological and Histological Changes after Treatment of Uterine Leiomyomas with Danazol or Buserelin

In: Journal of Obstetrics and Gynaecology · 1995 · vol. 21(1) , pp. 1–7 · doi:10.1111/j.1447-0756.1995.tb00889.x · PMID:8591104 · W2052437881
article OA: closed CC0 ⤵ 3 in-corpus citations
View on OpenAlex View on PubMed View at publisher
AI-generated summary by gemini-2.5-flash-lite, 2026-07-29

Buserelin treatment of uterine leiomyomas resulted in greater myoma shrinkage and hyaline degeneration than danazol, likely due to lower estradiol levels.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The following results were obtained from our investigations performed to compare the effects of danazol (400 mg/day orally for 4 to 6 months, n = 164) with those of buserelin (900 micrograms/day intranasally for 4 to 6 months, n = 83) on patients with uterine myomas. The effectiveness of buserelin (76.1%) in shrinking uterine myomas was better than that of danazol (56.7%). The serum-estradiol and progesterone levels were lower in the buserelin group than in the danazol group. The estrogen and progesterone receptors in a hysterectomied uterus were positively stained even at the end of those therapies. The degree and frequency of hyaline degeneration were higher in the buserelin group than in the danazol group. Thus, the shrinking of uterine myomas and the degree of hyaline degeneration might be caused by the lowering of uterine-tissue hormones, particularly of estradiol levels.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

Cited by (3)

References (4)

Cited by (3)

Source provenance

openalex
last seen: 2026-05-11T06:27:45.971503+00:00
License: CC0 · commercial use OK